XOMA Royalty (XOMA) Share-based Compensation Growth (3y) (2013 - 2026)
XOMA Royalty (XOMA) Share-based Compensation Growth (3y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Nanobiotix | 1,769.80 Bn | 1,769.74 Bn | - | - |
| 2 | Akari Therapeutics | 1,009.43 Bn | 1,009.43 Bn | - | - |
| 3 | BeOne Medicines | 473.64 Bn | 468.85 Bn | 1.35 Bn | -50.27% |
| 4 | Vertex Pharmaceuticals | 123.74 Bn | 116.49 Bn | 2.59 Bn | -0.04% |
| 5 | Regeneron Pharmaceuticals | 71.73 Bn | 62.97 Bn | 3.31 Bn | 38.45% |
| 6 | Belite Bio | 62.10 Bn | 62.10 Bn | - | - |
| 7 | Argenx Se | 54.68 Bn | 49.49 Bn | 1.41 Bn | - |
| 8 | Alnylam Pharmaceuticals | 38.13 Bn | 35.12 Bn | 959.66 Mn | - |
| 9 | Revolution Medicines | 36.21 Bn | 36.21 Bn | - | - |
| 10 | XOMA Royalty | 478.42 Mn | 412.34 Mn | - | 124.94% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 124.94% |
| Dec 31, 2025 | -24.74% |
| Jun 30, 2025 | -5.78% |
| Mar 31, 2025 | 41.34% |
| Dec 31, 2024 | 856.79% |
| Sep 30, 2024 | 49.25% |
| Jun 30, 2024 | 51.87% |
| Mar 31, 2024 | 145.64% |
| Dec 31, 2023 | 71.35% |
| Sep 30, 2023 | 56.56% |
| Jun 30, 2023 | 40.92% |
| Mar 31, 2023 | 11.81% |
| Dec 31, 2022 | -54.79% |
| Sep 30, 2022 | -18.59% |
| Jun 30, 2022 | -6.10% |
| Mar 31, 2022 | -5.90% |
| Dec 31, 2021 | -78.20% |
| Sep 30, 2021 | -2.75% |
| Jun 30, 2021 | -0.09% |
| Mar 31, 2021 | 65.10% |